Study on the Effects of Wheat and Corn Germ Blend Oil on Antioxidation and Immune Regulation of Dyslipidemia Population

Sponsor
Southeast University, China (Other)
Overall Status
Active, not recruiting
CT.gov ID
NCT06060509
Collaborator
Chinese Nutrition Society (Other), Zhongda Hospital (Other)
102
1
2
9
11.3

Study Details

Study Description

Brief Summary

The goal of this clinical trial is to explore the role of wheat and corn germ blended oils in regulating oxidative stress and immunomodulation in dyslipidaemic populations, to explore their effects on intestinal flora, antioxidant and immunomodulation. The main questions it aims to answer are:

  • How does phytosterol-rich wheat corn germ blended oil affect oxidative stress and immune function in dyslipidaemic people compared to peanut oil?

  • How does phytosterol-rich wheat corn germ blended oil affect serum metabolites, serum fatty acid profile, and intestinal flora in dyslipidaemic populations compared to peanut oil? What are the specific mechanisms involved?

Participants will be randomly assigned to the intervention and control groups, the packaging of germ oil and peanut oil will have a uniform appearance, and participants will be instructed to replace their household cooking oils with the distributed cooking oil for three months, in addition to replacing all the canteens in the staff units with the trial oil for more than three months. Participants did not know who was the control oil, germ oil or peanut oil, and both were randomly distributed to different groups of participants by the third-party supervisors.

Researchers will compare peanut oil to see if phytosterol-rich germ oil can improve oxidative stress and immune function in dyslipidaemic populations, in addition to exploring possible underlying mechanisms of improvement using multi-omics techniques.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Phytosterol-rich Wheat and Corn Germ Blended Oil
  • Dietary Supplement: Peanut oil
N/A

Detailed Description

The design of this intervention trial was a randomised controlled trial, in which the included dyslipidaemic population was randomly divided into a wheat corn germ blended oil intervention group and a peanut oil control group, with the male/female ratio, age, and level of basic clinical characteristics balanced between the two groups. The entire test phase consisted of a 14-day washout period and a 3-month intervention period. Participants in the intervention and control groups first entered a 14-day peanut oil washout period, which was followed by a three-month intervention phase. During the intervention phase, two different cooking oils (25-30 g of cooking oil per day according to the recommended intake of the Chinese Nutrition Society) were allocated to the two groups, with peanut oil being consumed by participants in the control group, and germ oil being used to replace the daily cooking oil for participants in the intervention group. After the participants were randomised into groups, they were provided with lunch and dinner according to the Chinese Dietary Guidelines for Residents of China and the local dietary habits of Nanjing, China, and breakfast was provided by the subjects themselves (dietary guidance was given to the subjects during the course of the study, and breakfast recipes were provided uniformly in order to achieve consistency between the two groups), and the intervention period was 3 months. Throughout the project period, all subjects followed their normal dietary habits and maintained a normal level of physical activity.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
102 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a randomised controlled intervention trial.This is a randomised controlled intervention trial.
Masking:
Double (Participant, Outcomes Assessor)
Masking Description:
The packaging of intervention oil and control oil was consistent, and the subjects could not distinguish what was blend oil and what was control oil. Blinding was also used for outcome assessors, who did not distinguish between the intervention and control groups.
Primary Purpose:
Supportive Care
Official Title:
Effects of Phytosterol-rich Wheat Corn Germ Blended Oil on Immune Function, Oxidative Stress, Serum Metabolites and Intestinal Flora in Dyslipidaemic Population: A Randomised Controlled Trial
Actual Study Start Date :
Mar 1, 2023
Actual Primary Completion Date :
May 1, 2023
Anticipated Study Completion Date :
Nov 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Wheat corn germ blended oil group

Participants in the intervention group replaced the daily cooking oil with wheat and corn germ oil, and were given 25-30 g of cooking oil per day according to the recommended intake of the Chinese Nutrition Society. Lunch and dinner were cooked using a uniform recipe for both intervention and control groups, and breakfast was self-cooked under the uniform dietary guidelines.

Dietary Supplement: Phytosterol-rich Wheat and Corn Germ Blended Oil
Blending of corn germ oil and wheat germ oil supplied by Yihai Kerry to obtain germ blended oil with high phytosterol content.

Other: Peanut oil group

Participants in the Peanut oil group replaced the daily cooking oil with Peanut oil, and were given 25-30 g of cooking oil per day according to the recommended intake of the Chinese Nutrition Society. Lunch and dinner were cooked using a uniform recipe for both intervention and control groups, and breakfast was self-cooked under the uniform dietary guidelines.

Dietary Supplement: Peanut oil
Participants in the control group consumed peanut oil daily for cooking.

Outcome Measures

Primary Outcome Measures

  1. Height in metres [12 weeks]

    Height in metres, physiological parameter

  2. Weight in kilogram [12 weeks]

    physiological parameter

  3. body mass index (BMI) [12 weeks]

    BMI= Weight (kg)/height^2(m)

  4. waist circumference [12 weeks]

    Unit in centimetres,physiological parameter

  5. hip measurement [12 weeks]

    Unit in centimetres,physiological parameter

  6. Systolic blood pressure [12 weeks]

    Units in mmHg. physiological parameter.

  7. diastolic blood pressure [12 weeks]

    Units in mmHg. physiological parameter.

  8. Serum triglyceride concentrations [12 weeks]

    physiological parameter

  9. Serum triglycerides concentrations [12 weeks]

    physiological parameter

  10. Serum LDL cholesterol concentrations [12 weeks]

    physiological parameter

  11. Serum HDL cholesterol concentrations [12 weeks]

    physiological parameter

  12. Percentage of CD3+ total T cells [12 weeks]

    physiological parameter

  13. Percentage of CD4+ T cells [12 weeks]

    physiological parameter

  14. Percentage of CD8+ T cells [12 weeks]

    physiological parameter

  15. Percentage of CD4+ CD8+ cells [12 weeks]

    physiological parameter

  16. Percentage of CD19+ B cells [12 weeks]

    physiological parameter

  17. Percentage of CD16/56+ NK cells [12 weeks]

    physiological parameter

  18. Immunoglobulin G [12 weeks]

    physiological parameter

  19. Immunoglobulin A [12 weeks]

    physiological parameter

  20. Immunoglobulin M [12 weeks]

    physiological parameter

  21. Complement C3 [12 weeks]

    physiological parameter

  22. Immunoglobulin E [12 weeks]

    physiological parameter

  23. reactive oxygen species [12 weeks]

    physiological parameter

  24. superoxide dismutase [12 weeks]

    physiological parameter

  25. malondialdehyde [12 weeks]

    physiological parameter

  26. glutathione [12 weeks]

    physiological parameter

Secondary Outcome Measures

  1. Lipoprotein a [12 weeks]

    physiological parameter

  2. leptin [12 weeks]

    physiological parameter

  3. Transforming growth factor-β [12 weeks]

    physiological parameter

  4. diamine oxidase [12 weeks]

    physiological parameter

  5. endotoxin [12 weeks]

    physiological parameter

  6. Number of participants who smoke [12 weeks]

    questionnaire

  7. Number of participants taking lipid-lowering drugs [12 weeks]

    questionnaire

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Male or female aged 18-65 with BMI less than 30;

  • At least one item meets the diagnostic criteria for dyslipidemia (2016 Chinese adult dyslipidemia prevention and treatment guide)

  • No serious complications related to liver, kidney, digestive tract, endocrine diseases and chronic diseases;

  • Within 3 months, he did not use the drugs and dietary supplements related to reducing blood fat and weight, and agreed not to use the above foods or drugs during the experiment;

  • Volunteer to participate in this study after listening to the project introduction and sign the informed consent form.

Exclusion Criteria:
  • Pregnant, pregnant or lactating women;

  • Patients with liver and kidney dysfunction, diabetes, coronary heart disease, hyperthyroidism, malignant tumor, asthma and other chronic diseases other than dyslipidemia;

  • Endocrine disease patients, postoperative patients, patients receiving hormone therapy and psychotic patients;

  • Have special eating habits: vegetarian, ketogenic diet (high fat, low carbon water), etc;

  • Those who cannot follow the test requirements.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Zhongda Hospital, Affiliated to Southeast University Nanjing Jiangsu China 210000

Sponsors and Collaborators

  • Southeast University, China
  • Chinese Nutrition Society
  • Zhongda Hospital

Investigators

  • Study Director: Gui-ju Sun, phD, Chinese Nutrition Society

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jia-yue Xia, Principal Investigator, Southeast University, China
ClinicalTrials.gov Identifier:
NCT06060509
Other Study ID Numbers:
  • 2022ZDSYLL031-P02
  • CNS-NNSRG2021-39
First Posted:
Sep 29, 2023
Last Update Posted:
Oct 5, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Jia-yue Xia, Principal Investigator, Southeast University, China
Additional relevant MeSH terms:

Study Results

No Results Posted as of Oct 5, 2023